drugset / Trial / NCT03775525
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Phase 1
Unknown
127 enrolled
Genzada Pharmaceuticals USA, Inc.
Translational Drug Development · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma
Timeline
- Start
- 2019-03-01
- Primary completion
- 2023-05
- Completion
- 2023-12
Publications
- Booth L, Roberts JL, Spasojevic I, Baker KC, Poklepovic A, West C, Kirkwood JM, Dent P. GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17;15:328-344. doi: 10.18632/oncotarget.28586.
- Booth L, West C, Von Hoff D, Dent P. Mechanisms of GZ17-6.02 resistance. Anticancer Drugs. 2022 Jun 1;33(5):415-423. doi: 10.1097/CAD.0000000000001203.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | GZ17-6.02 | Unknown | 375 mg | Oral |